TRAVERE THERAPEUTICS, INC. Inventory Write-down
TRAVERE THERAPEUTICS, INC. (TVTX) reported Inventory Write-down of $684.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. inventory write-down for the quarter ending 2022-12-31 was -$1.03M.
- TRAVERE THERAPEUTICS, INC. inventory write-down for the quarter ending 2022-09-30 was $329.00K, a 19.76% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. inventory write-down for the quarter ending 2022-06-30 was $792.00K, a 66.74% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. inventory write-down for the quarter ending 2022-03-31 was $949.00K, a 94.87% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. inventory write-down for fiscal 2025 was $684.00K, a 75.74% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. inventory write-down for fiscal 2024 was $2.82M, a 7.24% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. inventory write-down for fiscal 2023 was $3.04M, a 192.49% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. inventory write-down for fiscal 2022 was $1.04M, a 108.63% increase from fiscal 2021.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month | Inventory Write-down 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $684.00K 10-K · filed 2026-02-19 | ||||
| 2024-12-31 | $2.82M 10-K · filed 2026-02-19 | ||||
| 2023-12-31 | $3.04M 10-K · filed 2026-02-19 | ||||
| 2022-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$702.00K derived: sum of 2 quarters · filed 2025-02-21 | $90.00K derived: sum of 3 quarters · filed 2025-02-21 | $1.04M 10-K · filed 2025-02-21 | $2.46M 10-K · filed 2023-02-23 |
| 2022-09-30 | $329.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $1.12M derived: sum of 2 quarters · filed 2022-10-27 | $2.07M 10-Q · filed 2022-10-27 | $1.20M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-06-30 | $792.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.74M 10-Q · filed 2022-08-04 | $867.00K derived: sum of 3 quarters · filed 2024-02-20 | $1.28M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-03-31 | $949.00K 10-Q · filed 2022-05-05 | $75.00K derived: sum of 2 quarters · filed 2024-02-20 | $485.00K derived: sum of 3 quarters · filed 2024-02-20 | $960.00K derived: sum of 4 quarters · filed 2024-02-20 | |
| 2021-12-31 | -$874.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$464.00K derived: sum of 2 quarters · filed 2024-02-20 | $11.00K derived: sum of 3 quarters · filed 2024-02-20 | $498.00K 10-K · filed 2024-02-20 | $2.11M 10-K · filed 2022-02-24 |
| 2021-09-30 | $410.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $885.00K derived: sum of 2 quarters · filed 2022-10-27 | $1.37M 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | $475.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $962.00K 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $487.00K 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $2.23M 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $1.47M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |